Form 4: Immunovant's Chief Medical Officer Sells Shares to Cover Tax Obligations

Michael Geffner, Immunovant's Chief Medical Officer, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On April 9, 2025, Michael Geffner, the Chief Medical Officer of Immunovant, Inc., sold 6,169 shares of common stock at a weighted average price of $12.99.
• The sale was mandated by Immunovant to cover tax withholding obligations associated with the vesting of 13,744 restricted stock units (RSUs) on April 2, 2025, which were part of a grant of 54,978 RSUs from April 2, 2024.
• Following the transaction, Geffner directly owns 227,719 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transaction is related to tax obligations and doesn't indicate a change in the executive's view of the company.

Industry Context

This is a routine transaction related to executive compensation and tax obligations. It doesn't necessarily reflect a change in the executive's confidence in the company's prospects.

Stakeholder Impact

• The sale of shares may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small number of shares sold.

Key Dates

Keywords

Immunovant, IMVT, Michael Geffner, Chief Medical Officer, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Beneficial Ownership